Please ensure Javascript is enabled for purposes of website accessibility

3 Stocks That Could Lose You a Lot of Money

By Maxx Chatsko - Oct 8, 2017 at 11:10AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's probably best to stay away from Ziopharm, Civeo Corp, and Intrepid Potash.

Even the most successful investors swing and miss from time to time. It's a big, messy world out there, and no one has all the information they need to scout out only winning stocks for their portfolios. All individual investors can easily relate.

That said, it's probably best to steer clear of investing opportunities that sport a high degree of risk and low chance of success, especially when there's a pile of evidence pointing to that. Ziopharm Oncology (ZIOP 4.84%), Civeo Corp (CVEO -1.12%), and Intrepid Potash (IPI -1.28%) each offer investors the promise of growth and above-average returns in the future, but I think it's more likely they could lose you a lot of money.

An arm holding up a red flag against a blue sky.

Image source: Getty Images.

Completely dependent on a single partner

Ziopharm has quite the enthusiastic group of followers. The biopharma stock was nearly left for dead in early 2013 when its drug platform at the time was essentially declared a failure but has clawed its way back to life by focusing on new oncology drugs.

That's all well and good, but the company is entirely dependent on technology licensed from synthetic biology conglomerate Intrexon. The dependency is mutual. In fact, Ziopharm accounted for nearly 20% of its partner's total revenue in the first half of 2017.

ZIOP Chart

ZIOP data by YCharts.

Here's the thing: Exactly zero of the seven Intrexon technologies listed on Ziopharm's website have a track record to brag about. That wouldn't be so bad if they were new and novel, but all except one (ActoBiotics) are quite old and were gobbled up at bargain basement prices for the simple reason that they were thought to be next to worthless. Repackaging them with shiny new slides and marketing graphics doesn't change that.

The way to view the partnership is one of mutual convenience, not one that will change the world or even has a decent shot at success. Ziopharm needed something to pivot to in order to keep the lights on post-2013. Intrexon is waiting to commercialize several products it hopes can generate meaningful revenue but doesn't want to evaporate shareholder capital in the years that will take, so it collects rent from small- and micro-cap partners on worthless technology.

By the time Ziopharm's pipeline is exposed for what it is, Intrexon will no longer have a need for the biopharma's partnership. The small-cap company will not be able to move on so easily if it even survives. Stay very far away from this biopharma stock.

Good idea on paper, poor prospects in reality

Civeo Corp. is a workforce accommodation service provider focusing on natural resource extraction industries in remote areas. It provides housing, laundry, leisure, and other services to the men and women operating oil wells in Northern Canada and mining coal in the outback of Australia.

The stock has been on an absolute tear since mid-August, but the gains will be difficult to sustain. Why?

CVEO Chart

CVEO data by YCharts.

Civeo Corp. was a good idea not that long ago, but there's a reason Oil States International decided to spin off the business in mid-2014. The Canadian tar sands have become much less competitive with sub-$50-per-barrel oil. And although Australian coal remains relatively strong, it's facing political pressure domestically and competitive pressure internationally as the world increasingly demands more renewable energy usage. 

With the two main drivers of business losing steam, the company has been helpless to stop its top and bottom lines from steadily eroding. In fact, revenue has fallen nearly every single quarter since it went public in 2014. 

Unfortunately, there doesn't appear to be a recovery on the horizon. Civeo Corp.'s only solution offered to shareholders is to stabilize losses and clean up its balance sheet -- both of which have been accomplished recently. Then again, the company still reported an operating loss of $31 million in the first half of 2017. This is simply not a very good stock for buy-and-hold investors.

Do evaporation ponds have any other uses?

Intrepid Potash stock has been cruising all year despite a weak market for its potash fertilizer products. That's because Wall Street analysts have liked what they've seen so far from management's turnaround strategy, which focuses on lower-cost production processes and cleaning up the balance sheet.

You have to give credit where credit is due: Intrepid Potash has ramped up the use of solar evaporation ponds in an effort to lower production expenses, and has reduced its debt pile by $84 million -- more than half of its outstanding debt -- from the third quarter of 2016 to the second quarter of 2017. 

IPI Chart

IPI data by YCharts.

However, the debt reduction has come on the heels of extraordinary dilution. Intrepid Potash has gone from having just 76 million shares outstanding at the end of 2016 to 130 million today. While that has eaten at shareholder returns, investors probably aren't complaining of a 102% gain this year alone.

So, what happens next? While the company has greatly reduced its losses in recent quarters, potash prices are currently at multi-year lows and don't show any signs of recovering soon. The future may be bleak as well. There's this little material called lithium that could make today's prices the new normal -- or worse. That could mean Intrepid Potash's operations have peaked for the foreseeable future, and that this is the best things will get for now. Therefore, if you buy the stock now, then you could be very disappointed.

What does it mean for investors?

There are pros and cons to every investment opportunity, but sometimes the downside outweighs the potential upside. It's easy to want Ziopharm's cancer therapeutics to change the world or result in drug approvals, but history and science suggests that's more than a long shot. Civeo Corp.'s business is a case study for slow-motion train wrecks. And although Intrepid Potash is controlling the things it can, market forces may prove difficult to overcome in the near future. I think if you invest in these three stocks today, then you could lose a lot of money. Investors beware.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ZIOPHARM Oncology, Inc. Stock Quote
ZIOPHARM Oncology, Inc.
ZIOP
$1.30 (4.84%) $0.06
Intrepid Potash, Inc. Stock Quote
Intrepid Potash, Inc.
IPI
$44.71 (-1.28%) $0.58
Civeo Corporation Stock Quote
Civeo Corporation
CVEO
$25.58 (-1.12%) $0.29
Oil States International, Inc. Stock Quote
Oil States International, Inc.
OIS
$5.41 (-0.18%) $0.01
Precigen, Inc. Stock Quote
Precigen, Inc.
PGEN
$1.41 (5.22%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.